Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder
Status:
Withdrawn
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study of SNC-102 in adult subjects
with cPTSD, added to pre-existing treatment that includes prazosin with or without other
psychotropic drugs.
Subjects will be treated with SNC-102 tablets or matching placebo on a BID basis for 8 weeks.
Subjects will be evaluated for the symptoms of combat-related posttraumatic stress disorder
(cPTSD) as measured by the Clinician Administered PTSD Scale (CAPS-5), compared with the
response to placebo.